Effect of Treatment with Colchicine After Acute Coronary Syndrome on Major Cardiovascular Events: A Systematic Review and Meta-Analysis of Clinical Trials

Overview

Journal Cardiovasc Ther

Publisher Hindawi

Date 2022 May 2

PMID 35495414

Authors

Erfan Razavi

Akam Ramezani

Asma Kazemi

Armin Attar

Affiliations

Soon will be listed here.

Abstract

Aim: Colchicine as an anti-inflammatory drug might be effective in the treatment of atherosclerosis, an inflammatory-based condition. The aim of this systematic review and meta-analysis was to evaluate the impact of colchicine on acute coronary syndrome (ACS).

Methods: We searched SCOPUS, PubMed, and Web of Science up to September 27, 2020. All clinical trials which evaluated the effect of colchicine on ACS patients and reported high-sensitivity C-reactive protein (hs-CRP) serum level or gastrointestinal (GI) adverse events with at least 5-day follow-up or death, myocardial infarction (MI), and stroke with at least 30-day follow-up as outcomes were included.

Results: Finally, seven publications were analyzed. The results of our study revealed that colchicine has a marginally significant effect on hs-CRP attenuation. Furthermore, colchicine manifested promising results by declining the risk of stroke by 70%. However, MI and primary composite endpoint did not differ between the colchicine and noncolchicine groups. Although colchicine did not significantly increase GI adverse events in the pooled analysis, the dose-dependent effect was detected. Low-dose consumption can avoid GI side effects of colchicine.

Conclusion: Colchicine has shown some molecular and clinical promising results in ACS patients. The lack of effect of colchicine on MI and all-cause mortality can be partly attributed to the limitations of previous studies. Since colchicine is an inexpensive and easy-to-access drug that has shown to be safe in low-dose regimens in the clinical setting; it would be worthy that future large-scale well-designed clinical trials address this issue by resolving the limitations of previous investigations.

Citing Articles

Role of C-Reactive Protein as a Predictor of Early Revascularization and Mortality in Advanced Peripheral Arterial Disease.

Di Stolfo G, Mastroianno M, Pacilli M, De Luca G, Coli C, Bevere E J Clin Med. 2025; 14(3).

PMID: 39941486 PMC: 11818854. DOI: 10.3390/jcm14030815.

Development of the first Iranian clinical practice guidelines for the diagnosis, treatment, and secondary prevention of acute coronary syndrome.

Sarrafzadegan N, Bagherikholenjani F, Shahidi S, Ghasemi G, Shirvani E, Rajati F J Res Med Sci. 2024; 29:32.

PMID: 39239072 PMC: 11376720. DOI: 10.4103/jrms.jrms_851_23.

C-reactive protein deficiency ameliorates experimental abdominal aortic aneurysms.

Fu Y, Liu H, Li K, Wei P, Alam N, Deng J Front Immunol. 2023; 14:1233807.

PMID: 37753091 PMC: 10518468. DOI: 10.3389/fimmu.2023.1233807.

Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence.

Cimmino G, Loffredo F, De Rosa G, Cirillo P Int J Mol Sci. 2023; 24(3).

PMID: 36768804 PMC: 9917272. DOI: 10.3390/ijms24032483.

Nanoparticle Based Cardiac Specific Drug Delivery.

Li D, Son Y, Jang M, Wang S, Zhu W Biology (Basel). 2023; 12(1).

PMID: 36671774 PMC: 9856055. DOI: 10.3390/biology12010082.

References

Leung Y, Hui L, Kraus V . Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015; 45(3):341-50. PMC: 4656054. DOI: 10.1016/j.semarthrit.2015.06.013. View

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick D . Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J Cardiol. 2011; 108(4):575-9. DOI: 10.1016/j.amjcard.2011.03.087. View

Liuzzo G, Biasucci L, Gallimore J, Grillo R, Rebuzzi A, Pepys M . The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331(7):417-24. DOI: 10.1056/NEJM199408183310701. View

Westman P, Lipinski M, Luger D, Waksman R, Bonow R, Wu E . Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. J Am Coll Cardiol. 2016; 67(17):2050-60. DOI: 10.1016/j.jacc.2016.01.073. View

Crittenden D, Lehmann R, Schneck L, Keenan R, Shah B, Greenberg J . Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012; 39(7):1458-64. PMC: 3733459. DOI: 10.3899/jrheum.111533. View

. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol. 1988; 12(6 Suppl A):3A-13A. DOI: 10.1016/0735-1097(88)92635-6. View

Ullah W, Narayana Gowda S, Fischman D . Safety and Efficacy of Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis. Cardiovasc Revasc Med. 2020; 23:1-6. DOI: 10.1016/j.carrev.2020.06.004. View

Sullivan G, Feinn R . Using Effect Size-or Why the P Value Is Not Enough. J Grad Med Educ. 2013; 4(3):279-82. PMC: 3444174. DOI: 10.4300/JGME-D-12-00156.1. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

11.

Tong D, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H . Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020; 142(20):1890-1900. DOI: 10.1161/CIRCULATIONAHA.120.050771. View

12.

Bhat A, Naguwa S, Cheema G, Gershwin M . Colchicine revisited. Ann N Y Acad Sci. 2009; 1173:766-73. DOI: 10.1111/j.1749-6632.2009.04674.x. View

13.

Katsanos A, Palaiodimou L, Price C, Giannopoulos S, Lemmens R, Kosmidou M . Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis. Eur J Neurol. 2020; 27(6):1035-1038. DOI: 10.1111/ene.14198. View

14.

Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou A, Zacharoulis A, Kolokathis F . Colchicine Pharmacokinetics and Mechanism of Action. Curr Pharm Des. 2018; 24(6):659-663. DOI: 10.2174/1381612824666180123110042. View

15.

Ridker P, Luscher T . Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014; 35(27):1782-91. PMC: 4155455. DOI: 10.1093/eurheartj/ehu203. View

16.

Tardif J, Kouz S, Waters D, Bertrand O, Diaz R, Maggioni A . Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381(26):2497-2505. DOI: 10.1056/NEJMoa1912388. View

17.

Lazzarotto C, Ronsoni M, Fayad L, Lourenco Nogueira C, Bazzo M, Narciso-Schiavon J . Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol. 2013; 12(4):599-607. View

18.

Shanbrom E, Rapoport L . Gastrointestinal complications of colchicine therapy in gout. Ann Intern Med. 1958; 48(3):655-60. DOI: 10.7326/0003-4819-48-3-655. View

19.

Shin J, Kim C, Jeon E, Sung C, Shin H, Choi J . Overexpression of C-reactive Protein as a Poor Prognostic Marker of Resectable Hepatocellular Carcinomas. J Pathol Transl Med. 2015; 49(2):105-11. PMC: 4367105. DOI: 10.4132/jptm.2015.01.19. View

20.

Roubille F, Cayla G, Picot M, Pradet V, Massin F, Gervasoni R . [C-reactive protein (CRP) after revascularized STEMI: is CRP a prognostic factor?]. Rev Med Interne. 2008; 29(11):868-74. DOI: 10.1016/j.revmed.2008.01.026. View